Mounjaro 16mg: is there a 16mg dose, and what actually comes after 15mg?

Why does the search for 'Mounjaro 16' keep coming up?

It is a fair question. People who have responded well at 12.5mg sometimes wonder whether pushing slightly beyond 15mg could produce better results, and dose numbers that look like round increments (2.5mg steps) might logically suggest a next rung. The curiosity is understandable. But Mounjaro's licensed strengths (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg) were set by Eli Lilly and verified by the MHRA based on the full tirzepatide clinical programme. No 16mg formulation was submitted, tested in a phase-three weight-management trial, or authorised anywhere. The number does not exist in clinical practice.

Some of the search traffic for 'Mounjaro 16' comes from people who have read about compounded or unlicensed versions of tirzepatide sold online. These products are a different matter entirely: they sit outside the licensed supply chain, carry no regulatory guarantee of dose accuracy, and should not be confused with the genuine Mounjaro KwikPen, which you can read more about here. The risks of sourcing tirzepatide outside a regulated pharmacy are documented and serious.

The MHRA's public guidance on GLP-1 medicines makes clear that these treatments are not assessed for cosmetic or quick weight loss, and that the licensed dose ceiling exists for a reason rooted in the trial evidence and safety profile of the medicine.

What actually happens at 15mg, the evidence behind Mounjaro's top dose?

The SURMOUNT-1 trial (a 72-week, double-blind study of tirzepatide in adults with obesity and no diabetes) found that participants receiving 15mg achieved an average body-weight reduction of around 20–21%, compared with roughly 3% on placebo. Those are the figures cited by NICE in their technology appraisal of tirzepatide (TA1026), which led to the recommendation for tirzepatide in NHS weight management for adults meeting specific eligibility criteria.

To put 15mg in context: the subsequent SURMOUNT-5 head-to-head trial compared tirzepatide directly with semaglutide 2.4mg (Wegovy) over 72 weeks and found tirzepatide produced the greater average weight reduction. That comparison involved adults with obesity and no diabetes, and was published in the New England Journal of Medicine in 2025. Reaching 15mg, then, is already arriving at the most effective dose of what is currently the most clinically studied dual-agonist available in the UK. There is no licensed tier above it.

Titration to 15mg typically takes around six months of four-weekly dose increases, starting from the 2.5mg starter pen, details of which are on our Mounjaro 2 page. Your prescriber will only progress your dose if your response and tolerance support it, the process is not automatic.

What happens if 15mg does not produce the results you hoped for?

NICE's guidance (TA1026) is direct on this point: if you have not achieved at least 5% weight loss after six months on the highest tolerated dose, continuing on Mounjaro should be reviewed by your clinician. That is not a failure of the medicine, it reflects the fact that individual responses vary, and that clinical supervision exists precisely to navigate those situations honestly. A prescriber might look at whether lifestyle factors, medication interactions, or an underlying condition are affecting results, and whether an alternative approach would serve you better.

For people exploring their options more broadly, the range of weight-management treatments licensed in the UK includes both tirzepatide and semaglutide-based options, each with different mechanisms and evidence bases. Understanding the full picture is easier with clinical input than by researching dose numbers that do not exist.

One thing worth knowing: the NHS patient information for tirzepatide includes clear guidance on what to do if you feel your dose is not working, including when and how to raise it with your prescribing team. Adjustments to your treatment plan should always go through your prescriber, not a forum, and certainly not a seller offering doses outside the licensed range.

What should you actually do if you are currently on 12.5mg and wondering about next steps?

If you are approaching 12.5mg and thinking about whether 15mg is right for you, that is precisely the conversation your clinical review is designed to support. At nume (sorry) at a service like ours, every repeat order is reviewed by a real prescriber before it is approved and dispensed. There is no auto-renewal. A clinician looks at your current dose, your progress, any side effects you have reported, and decides whether moving to the next strength is appropriate.

The Mounjaro prescribing process at a regulated UK pharmacy includes that review at each stage, not just at the start. If you have specific questions about where you are in your titration, or you are considering switching from another provider, our prescribers can work through the detail with you. Evidence of your current treatment is required for dose continuations, which is standard clinical practice and one of the reasons regulated services exist.

If you have been taking Mounjaro at 12.5mg and the next step feels like a big one, it is worth knowing that many people find the step to 15mg straightforward, a journey that begins at the 5mg stage, and the titration schedule is gradual by design. The background on how tirzepatide works as a dual GIP and GLP-1 receptor agonist can help make sense of why the dose progression is structured the way it is. Worth reading before your next review.